| Mantle Cell Lymphoma studied in …STUDIED_INderived200 of 706show all (up to 200) |
|---|
| → studied in | NCT05006716Phase 1/Phase 2 · recruiting A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06252675Phase 2 · recruiting Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06697184Phase 1/Phase 2 · recruiting A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06742996Phase 3 · recruiting A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03015896Phase 1/Phase 2 · completed Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma · condition mapped CURATED_BROADER · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04662255Phase 3 · active not recruiting Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) · condition mapped ALIAS · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06553872Phase 2 · recruiting Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06784167recruiting Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05471843Phase 1/Phase 2 · active not recruiting Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05861050Phase 1/Phase 2 · suspended Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07101328Phase 1 · recruiting A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) · condition mapped ALIAS · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06029309Phase 1/Phase 2 · recruiting Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05025800Phase 1/Phase 2 · active not recruiting ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07341191Phase 2 · recruiting Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02446236Phase 1 · active not recruiting Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02558816Phase 1/Phase 2 · completed A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03267433Phase 3 · active not recruiting Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04115631Phase 2 · active not recruiting A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07168486Phase 1 · enrolling by invitation CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01318317Phase 1/Phase 2 · active not recruiting Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07799220Phase 2 · not yet recruiting A Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03625037Phase 1/Phase 2 · active not recruiting First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma · condition mapped ALIAS · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07003295Phase 2 · recruiting Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy · condition mapped CURATED_BROADER · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07225439Phase 1 · recruiting Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06564038Phase 1/Phase 2 · recruiting A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06767891enrolling by invitation Real-world Study of Acalabrutinib · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01695941Phase 1 · active not recruiting Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05951959Phase 2 · active not recruiting A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05976763Phase 3 · recruiting Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07029737Phase 2 · recruiting A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04477486Phase 2 · completed Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04802590Phase 2 · active not recruiting Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07788118Phase 1/Phase 2 · recruiting A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04626791Phase 2 · active not recruiting Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07784101Phase 3 · not yet recruiting A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL). · condition mapped ALIAS · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05249959Phase 2 · active not recruiting Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients. · condition mapped CURATED_BROADER · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05294731Phase 1/Phase 2 · recruiting Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05458297Phase 2 · active not recruiting A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04007029Phase 1 · active not recruiting Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia · condition mapped CURATED_BROADER · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04880434Phase 2 · completed Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07673367Phase 2 · recruiting Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma · condition mapped CURATED_BROADER · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06980116Phase 1 · recruiting Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03440567Phase 1 · completed Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma · condition mapped CURATED_BROADER · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05495464early Phase 1 · active not recruiting A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06340737Phase 1 · recruiting AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03946878Phase 2 · active not recruiting Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma · condition mapped CURATED_BROADER · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05887167Phase 1 · recruiting Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04765111Phase 2 · active not recruiting Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05724121recruiting Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05990465Phase 1 · recruiting LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06533579Phase 1/Phase 2 · recruiting Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06675123Phase 1 · recruiting Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma · condition mapped CURATED_BROADER · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02213926Phase 2 · active not recruiting An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01804686Phase 3 · recruiting A Long-term Extension Study of PCI-32765 (Ibrutinib) · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07285044Phase 2 · recruiting The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07424833Phase 1 · recruiting A Study of APG-3288 in Relapsed/Refractory Blood Cancers · condition mapped ALIAS · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07609862Phase 1/Phase 2 · recruiting A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05365659Phase 1 · recruiting IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07272499Phase 2 · recruiting Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03478514Phase 2 · active not recruiting Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07121946Phase 1 · recruiting This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07082686Phase 2 · recruiting A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06) · condition mapped ALIAS · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01479842Phase 1 · active not recruiting Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma · condition mapped CURATED_BROADER · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07719556Phase 2 · recruiting Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL) · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04783415Phase 2 · active not recruiting Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05024045Phase 1 · completed Study of Oral LOXO-338 in Patients With Advanced Blood Cancers · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07711327not yet recruiting Atrial Fibrillation Among Patients With Hematologic Malignancies on Tyrosine Kinase Inhibitor Therapy · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03282396Phase 2 · active not recruiting Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02717624Phase 1 · active not recruiting A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04792489Phase 2 · recruiting DALY II USA/ MB-CART2019.1 for DLBCL · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06043011recruiting Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07697339Phase 1 · not yet recruiting HDM2005 Combination Therapy in Relapsed/Refractory Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05665062Phase 1 · active not recruiting Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06558604Phase 2 · recruiting Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05098613Phase 1 · recruiting Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06300528Phase 2 · active not recruiting Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01880567Phase 2 · active not recruiting Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03501576recruiting Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07684950Phase 2 · not yet recruiting Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05131022Phase 1 · recruiting A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02339922Phase 2 · active not recruiting Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04205409Phase 2 · completed Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies · condition mapped CURATED_BROADER · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01815749Phase 1 · active not recruiting Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03314974Phase 2 · recruiting Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03323151Phase 1/Phase 2 · completed A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07453095Phase 2 · recruiting Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07499128NA · enrolling by invitation Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event · condition mapped ALIAS · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06522386Phase 2 · active not recruiting GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03872180Phase 2 · active not recruiting Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03277729Phase 1/Phase 2 · active not recruiting A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas · condition mapped CURATED_BROADER · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04545762Phase 1 · recruiting Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05004064Phase 2 · active not recruiting Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07592481NA · not yet recruiting Connected Blood Pressure Monitoring in Patients With Hematologic Malignancies Initiating Covalent BTK Inhibitors · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00081874Phase 1/Phase 2 · completed RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05934838Phase 1 · active not recruiting A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01838434Phase 1 · completed Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05453396Phase 2 · terminated Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies · condition mapped CURATED_BROADER · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03162536Phase 1/Phase 2 · active not recruiting A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04566887Phase 2 · active not recruiting Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03622788Phase 1/Phase 2 · active not recruiting Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05978739Phase 2 · completed Evaluating Different Doses of Orelabrutinib in MCL · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02242097Phase 2 · completed Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma · condition mapped CURATED_BROADER · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05025423Phase 2 · terminated Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01661881Phase 2 · active not recruiting Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03494179Phase 1/Phase 2 · completed A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL) · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01415752Phase 2 · active not recruiting Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04054167Phase 2 · active not recruiting Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma · condition mapped CURATED_BROADER · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06224309completed Preliminary Assessment of [18F]BL40 in PET/CT Scans · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02972840Phase 3 · active not recruiting A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04600804completed The Role of 18F-FDG-PET for Staging and Prognostication · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04195633Phase 2 · recruiting Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02159755Phase 1 · active not recruiting Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma · condition mapped CURATED_BROADER · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02427620Phase 2 · active not recruiting Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01962636NA · terminated Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03710772Phase 2 · active not recruiting Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02797470Phase 1/Phase 2 · active not recruiting Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant · condition mapped CURATED_BROADER · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03246906Phase 2 · terminated Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01955499Phase 1 · active not recruiting Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02362035Phase 1/Phase 2 · completed ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06504199Phase 2 · active not recruiting Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07259070Phase 1/Phase 2 · recruiting Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma · condition mapped ALIAS · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07261163Phase 2 · recruiting Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06852638Phase 2 · recruiting CD70-targeted immunoPET Imaging of Malignant Cancers · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07578077Phase 1/Phase 2 · not yet recruiting Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma · condition mapped CURATED_BROADER · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07569965Phase 2 · not yet recruiting Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCL · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05529069Phase 2 · recruiting Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03035331Phase 1/Phase 2 · completed Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01231412Phase 3 · completed Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03863184Phase 2 · active not recruiting Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03479268Phase 1 · active not recruiting Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05245656Phase 2 · recruiting A Study Comparing Rituximab/Bendamustin(RB) Alternating With Rituximab/Bendamustin/Cytarabin(RBAC) With RB Therapy in Elderly Patients With Mentle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06263491Phase 2 · recruiting Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03523975Phase 1/Phase 2 · recruiting Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06839053Phase 2 · recruiting Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03623373Phase 2 · completed Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04939272Phase 1/Phase 2 · active not recruiting Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma · condition mapped CURATED_BROADER · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05020678Phase 1 · active not recruiting NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06859008Phase 1 · recruiting Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04189757Phase 2 · active not recruiting Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04491370Phase 1/Phase 2 · recruiting Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06544265Phase 1 · recruiting SynKIR-310 for Relapsed/Refractory B-NHL · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04911478active not recruiting Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04488354Phase 1 · completed Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05776134available Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06208735Phase 1 · recruiting CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02051257Phase 1 · active not recruiting Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02682641Phase 2 · active not recruiting Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06192888Phase 1 · active not recruiting A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04830137Phase 1 · recruiting A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02601313Phase 2 · completed Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2) · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02952508Phase 2 · active not recruiting Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03547115Phase 1 · terminated A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07476378NA · not yet recruiting A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell Malignancies · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04703686Phase 2 · completed Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy · condition mapped CURATED_BROADER · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06026319Phase 1 · recruiting CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06572618Phase 2 · recruiting Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02213913Phase 1/Phase 2 · completed Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas · condition mapped CURATED_BROADER · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07460362Phase 2 · recruiting Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma · condition mapped ALIAS · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06151730recruiting Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04186520Phase 1/Phase 2 · recruiting CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05432635Phase 1 · recruiting Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04282018Phase 1/Phase 2 · completed Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06854003Phase 2 · recruiting BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07412405NA · not yet recruiting This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including R · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04775745Phase 1 · recruiting Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05544019Phase 1 · recruiting Study of SGR-1505 in Mature B-Cell Neoplasms · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06191887Phase 1 · recruiting B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies · condition mapped CURATED_BROADER · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02858804Phase 4 · completed EDOCH Alternating With DHAP for New Diagnosed Younger MCL · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04368702NA · recruiting CONFIRM: Magnetic Resonance Guided Radiation Therapy · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04883437Phase 2 · recruiting Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04849416Phase 2 · completed A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05694364Phase 1 · completed Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07377578Phase 3 · recruiting A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06357676Phase 1/Phase 2 · recruiting Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01199562active not recruiting Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant · condition mapped CURATED_BROADER · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04116437Phase 2 · completed Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03740529Phase 1/Phase 2 · completed A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03842696Phase 1/Phase 2 · active not recruiting Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05665530Phase 1 · completed A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04855695Phase 1/Phase 2 · recruiting Avo In R/R And Previously Untreated MCL · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07077512Phase 2 · recruiting Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04223765Phase 1 · recruiting Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05716087Phase 2 · active not recruiting A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02896582Phase 2 · completed Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03674411Phase 2 · active not recruiting Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04882475active not recruiting Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study. · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06054776Phase 2 · recruiting Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06106841Phase 1/Phase 2 · terminated TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06022029Phase 1 · recruiting A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07285590Phase 2 · recruiting Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04191187Phase 2 · completed Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05602363Phase 1 · recruiting AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06004167NA · completed Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T) · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03567876Phase 2 · completed Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07264894Phase 4 · not yet recruiting ZSDT for the Treatment of R/R Mantle Cell Lymphoma After BTK Inhibitor Failure: a Multi-center Prospective Clinical Trial · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07257510NA · recruiting Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02568553Phase 1 · completed Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04484012Phase 2 · recruiting Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma · condition mapped CURATED_BROADER · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03816683completed A Disease Registry of Patients With Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05643742Phase 1/Phase 2 · recruiting A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies · condition mapped ONTOLOGY_EXACT · 706 trials mapped (198 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |